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Purpose/Objective: The atlas-based automatic segmentation can 
significantly reduce contouring time. A multi-atlas method has been 
shown to provide greater accuracy than a single best matched (SBM) 
method. In this work, we evaluated the multi-atlas based 
segmentation using majority voting approach for head and neck (H&N) 
and prostate cancer. 
Materials and Methods: 50 prostate atlases and 20 H&N atlases were 
developed and utilized for atlas-based segmentation. Prostate atlas 
contained CT images and manually defined contours of the prostate, 
seminal vesicles, rectum and bladder. H&N atlas contained CT images 
and manually defined contours of the brain stem, spinal cord, 
parotids, constrictor muscle, larynx, oral cavity and thyroid. SBM used 
one automatically selected best match atlas. Multi-atlas used multiple 
automatically selected best matches (3, 4, 5, and 10, respectively). 
And, the final segmentation fused the individual segmentations using 
majority vote rule. We performed automatic segmentation using SBM 
and multi-atlas for 10 prostate subjects and 10 H&N subjects. Average 
dice coefficients were calculated for each structure to compare 
against manually defined contours for subjects. 
Results: In prostate case, average dice coefficients of multi-atlas (3, 
4, 5, and 10) and SBM were 0.686 ± 0.192, 0.693 ± 0.192, 0.716 ± 
0.208, 0.768 ± 0.141 and 0.650 ± 0.182, respectively. There was a 
statistically significant difference between SBM and multi-atlas: 10 (P 
= 0.0014). In H&N case, average dice coefficients of multi-atlas (3, 4, 
5, and 10) and SBM were 0.709 ± 0.176, 0.737 ± 0.159, 0.740 ± 0.157, 
0.757 ± 0.132 and 0.715 ± 0.166, respectively. There was a 
statistically significant difference between SBM and multi-atlas: 10 (P 
= 0.0062). 
Conclusions: The multi-atlas based segmentation using majority 
voting was greater accuracy than SBM for H&N and prostate cancer. 
The multi-atlas based segmentation was more accurate with 
increasing the number of fused atlas. 
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Purpose/Objective: To compare the TomoTherapy® System's 
TomoDirect™ modality to the standard 3DRT technique for the 
postoperative breast radiotherapy. 
Materials and Methods: We compared the treatment plans of 30 
patients consecutively treated from February to May 2012 with the 
new TomoTherapy® System's TomoDirect™ (TD) modality for 
postoperative breast radiotherapy. The TomoDirect™ was 
implemented in our Institute from January 2012. Clinical target 
volumes (CTV) and organs at risk (OAR) were contoured for all the 
patients by the same physician to avoid interobserver variability; a 
PTV was generated by adding a 5 mm uniform margin to the CTV. 
Patients underwent the whole breast irradiation and a simultaneous 
integrated boost to the tumor bed region. The prescribed doses (at 
the 95% isodose) were 2.25-2.50 Gy/fraction up to a total dose of 45-
50 Gy (20 fractions) to the whole breast and to the postsurgical area 
respectively. Plans for TD and 3DRT were both optimized, according 
to our Intitutional protocol, in terms of dose coverage to target and 
constraints. The constraints routinely used refer to a dose of 
2Gy/fraction andare: PTV(breast), V95%≥95%, D50%£108%, 
V100%(boost dose)£30%, Dmax£115%; PTV(boost), V95%≥95%, 
Dmax<115%; Heart (right breast),Dmax<16-20Gy,V8Gy<10-15%; Heart 
(left breast), D5%<16-20Gy,V8Gy<30-35%;Heart (right/left breast) 
Dmean<3.2-4Gy; Ipsilateral lung V16Gy<15-20%,V8Gy<35-40%, 
V4Gy<50%, Controlateral lung V4Gy<10-15%;Controlateral breast 
Dmax<2.4-2.6Gy. 
Results: The dosimetric comparison related to the PTVs and to the 
OARs DVHs are reported in the Table as mean values (%) plus/minus 
the standard deviation (%). Controlateral breast maximum dose 
resulted: 2.9±2.6Gy, 2.5±2.2Gy for 3DCRT andTD respectively, while 
Controlateral lung maximum dose is about 0 Gy in both cases. 
Concerning the treatment time and the planned monitor units, the 
firsts where378±55s and 95±15s while the monitor units were 




Conclusions: TD was investigated as an alternative technique to the 
3D conformal one for the postoperative breast radiotherapy. DVHs 
show an improvements in PTV coverage and Heart sparing. On the 
contrary, the treatment time and the monitor units of the TD 
technique are about 4 and 18 times those of the 3DRT. The real 
advantage of the TomoDirect™ is the possibility of performing the 
image guided radiotherapy and in this case results suggest that the 
use of the TD technique is definitely favourable. 
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Purpose/Objective: To investigate the advanced radiotherapy 
treatments of cutaneous Kaposi’s sarcoma of lower extremities with 
adequate target coverage and bone high sparing with volumetric 
modulated arc therapy (VMAT, RapidArc (RA)) in comparison to 
electron beams. 
Materials and Methods: Ten patients were planned with RA and, 
alternatively, with electron beams. Patients presented superficial 
target volumes adjacent to the leg’s bones and extending from the 
knees to the base of the foot in 7out of 10. Target volume longitudinal 
length was in average 45±12cm (range 29-66 cm). Dose was prescribed 
to 30Gy in 10 fractions to mean planning target volume (PTV), and 
significant maximum dose to the bone was limited to 30Gy. Plans 
were designed for 6MV photon beams for RA and 6MeV for electrons. 
For RA two groups of plans were generated: the first, RA_1, with the 
aim of respecting planning objectives for target coverage, 
homogeneity and maximum dose to the bones, the second group, 
RA_2,was generated adding the request to maximise bone sparing 
without significant compromises to target objectives. Dose 
distributions were computed with AcurosXB for photons and with 
Monte Carlo for the electrons. 
Results: Given the specificity of the target, PTV coverage was 
acceptably for both RA_1 (V95%>95%,V107%<0.5%) and RA_2 plans 
(V90%>95% V107%<5.0%) respecting the objective of a bone sparing with 
D2%<30Gy, while, although acceptable for bone involvement, 
pronounced target coverage violations were obtained for electron 
plans. MU resulted comparable for electrons and RA although the 
latter increased when a superior bone sparing was imposed, reaching, 
however, a significant improvement also respect electrons plans on all 
the analyzed parameters for bone DVHs (D2%, D10cm3 and D20cm3, and Vx 
with x=10, 20, 30Gy, mean dose). Delivery time were 12.1±4.0 
minutes for electrons and 4.8±1.3 minutes for the most modulated RA 
plans (RA_2). 
Conclusions: High plan quality was shown for Kaposi sarcoma in the 
lower extremities using VMAT and this might simplify the management 
of these treatments in comparison to more conventional usage of 
electrons, particularly in institutes with limited staff resources and 
heavy workloads. In addition, VMAT demonstrated dosimetrically 
extremely advantageous and a flexible approach also in a typology of 
treatments where electron beam therapy is mainly considered to be 
effective due to the limited penetration of the beams.  
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Purpose/Objective: To compare dose sparing to stomach, duodenum 
and small bowel using radiobiological endpoints for 3D and intensity-
modulated arctherapy (IMAT) plans for locally advanced pancreatic 
cancer (LAPC). 
Materials and Methods: For 11 patients treated with chemo-
radiotherapy, the original 3D conformal treatment plan (50.4 Gy / 28 
fr to the tumour and elective nodes, PTV5040, then 9 Gy / 5 fr to the 
primary tumour, PTV5940) was compared retrospectively to an IMAT 
plan with a simultaneous integrated boost(59.4 Gy (PTV5940) and 52 
Gy (PTV5040) in 33 fractions). In both techniques, target coverage 
(D99% >95% prescribed dose) and dose constraints to critical organs 
(cord Dmax< 40 Gy, liver D50% <20 Gy and kidneys, R kidney D50%< 20 Gy, 
L kidney D30% < 20 Gy) were strictly respected. Plans were compared 
using the PTV conformity index CI95% and dose metrics of gastro-
intestinal (GI) organs (stomach: V50 and Dmax to 2cc, combined stomach 
and duodenum (StoDuo): V50 and small bowel: V45). NTCP modelling of 
stomach, duodenum and small bowel was used to rank plans by 
estimating GI toxicity, using the full range of NTCP parameter values 
for these organs found in the literature. 
Results: Improved dose sparing of critical organs for all 11 patients 
was observed with the IMAT technique, due to higher dose 
conformation of the target volume: IMAT mean PTV5940 CI95%= 1.08 ± 
0.03 vs 3D mean PTV5940 CI95% = 1.83 ± 0.25, p<0.001. In particular, 
dose constraints for L kidney were met for 11/11 patients for IMAT 
and only 6/11 for 3D. A reduction in acute toxicity of small bowel may 
be possible using IMAT due to the reduction of the V45 volume (IMAT 
mean 285.1 ±124.1 cm3 vs 3D mean 348.8±147.3 cm3, p<0.001). A 
similar reduction in high dose was seen for StoDuo when using IMAT: 
StoDuo V50 (IMAT mean 26.4±5.8 cm3 vs 3D mean 33.7±8.1 cm3 
p<0.0001). For stomach, although there was no significant difference 
in the two techniques for the Stomach Dmax (3D mean = 59.7±2.6 Gy 
and IMAT mean= 58.3±3.6 Gy), a reduction in the Stomach V50 volume 
was observed with IMAT (IMAT mean 18.7±12.3 cm3 vs 3D mean 
28.1±20.4 cm3, p=0.009). Using NTCP estimates of GI toxicity to rank 
plans showed that the IMAT technique was always preferable to 3D 
conformal therapy, independent of the values used in the 
radiobiological modelling.  
Conclusions: The predicted dose sparing obtained with the IMAT 
technique is particularly important in the context of concurrent 
chemo-radiotherapy for pancreatic cancer where GI toxicity is often a 
limiting factor. For stomach, duodenum and small bowel, NTCP 
analysis predicts a significant advantage in using IMAT. Using 
radiobiological endpoints presents a simple method for obtaining 
relative plan ranking, which is robust to the choice of values used in 
the NTCP modelling.  
   
PO-0814   
Dose escalation with simultaneous IMRT for anal cancer with 
minimum bowel toxicity 
C. Brooks1, Y. Lee1, V. Hansen1, D. Tait2, M. Hawkins3 
1The Royal Marsden NHS Foundation Trust, Joint Department of 
Physics, Sutton, United Kingdom  
2The Royal Marsden NHS Foundation Trust, Department of Clinical 
Oncology, Sutton, United Kingdom  
3Gray Institute for Radiation Oncology and Biology, Department of 
Oncology, Oxford, United Kingdom  
 
Purpose/Objective: Higher tumour stage is an independent predictor 
of local failure. We present a retrospective planning study to 
determine the feasibility of dose escalation in very advanced anal 
cancers using a simultaneous integrated boost (SIB) with a small bowel 
dose constraint of V30Gy≤300cc (Devisetty et al 2009).  
Materials and Methods: Five consecutive CT datasets of patients with 
stage T3N2-T4N3 anal canal were identified. Planning target volume 1 
(PTV1) included tumour and pelvic elective nodal areas; PTV2 
included primary tumour and involved nodes. Three types of IMRT 
plans were generated. The CLINICAL plan utilised a sequential phase1 
inverse-planned 7-field IMRT followed by either a conformal or 
inverse-planned phase 2. The SIB plans were prescribed 42Gy in 
1.5Gy/fraction to PTV 1 and 50.4Gy (SIB1.8) and 56Gy (SIB2.0) to PTV2 
respectively. Prescription dose to the CLINICAL plan was 30.6Gy and 
19.8Gy in 1.8Gy/fractions to PTV1 and PTV2 respectively. The plans 
were optimised to meet small bowel, genitalia, bladder and femoral 
head constraints. Patients were previously treated with the CLINICAL 
plan and did not experience high grade acute bowel toxicity. 
Maintaining the same risk of gastro-intestinal toxicity as achieved in 
the CLINICAL plan was a priority. The CLINICAL plan was used as the 
reference and the small bowel dose constraint V30Gy≤300cc was aimed 
for in the SIB plans. Small bowel V30Gy and coverage of PTV2 by 95% 
prescription isodose and conformity index (CI) were compared.  
Results: All plans achieved the minimum dose coverage of 95% 
prescription dose. No plan exceeded a maximum dose of 105% to 2% of 
the PTV volume. The SIB test arms had better conformity index (CI) 
than the clinical plan. 4/5 patients met the bowel dose constraint of 
V30Gy≤300cc. One case failed to achieve small bowel constraint as 
223cc bowel overlapped PTV. 
 









PTV D98% (Gy) 49.0 (48-49.4) 48.3 (47.9-48.5) 53.5 (53.5-53.9) 
PTV D2% (Gy) 51.9 (51.7-52.3) 52.3 (52.2-52.4) 58 (57.8-58.4) 
PTV D50% (Gy) 50.6 (50.4-50.7) 50.4 (50.4-50.5) 55.9 (55.9-56.1) 
PTV D95% (Gy) 49.3 (48.8-49.7) 48.7 (48.4-48.9) 54 (54-54.3) 
CI 1.40 1.15 1.15 
 
  
Conclusions: SIB IMRT is achievable whilst meeting the bowel 
constraint of V30Gy≤300cc providing that the physical volume of the 
bowel and PTV overlap is kept below 190cc. Acceptable small bowel 
dose increases are seen in the SIB plans compared to the clinical plan. 
Dose escalation is achievable for prescription doses of 50.4Gy and 
56Gy to the primary volume and plans for escalation to 64.4Gy are in 
progress. 
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Purpose/Objective: The accurate and fast dose calculation is an 
essential requirement of modern Radiotherapy (RT).The ability to 
predict dose with high accuracy is usually associated with the 
probabilistic Monte Carlo methods, but with long calculation times for 
use in daily clinical practice. The dose-calculation algorithms used in 
clinical practice, such as pencil-beam convolution and the 
convolution/superposition (method used in Anisotropic Analytical 
Algorithm - AAA) typically include models to significantly reduce the 
computation time (pre-calculated dose kernels in water with Monte 
Carlo), but with decreasing accuracy, especially in the presence of 
heterogeneities. The deterministic dose-calculation algorithm Acuros® 
XB for photons, which was recently implemented in the treatment 
planning system (TPS) Eclipse™ is able to fulfill these two 
